SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-329533"
 

Search: id:"swepub:oai:DiVA.org:uu-329533" > Outcomes in a Warfa...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Björck, FredrikUmeå universitet,Medicin,Sundsvall Research Unit, Umeå University (author)

Outcomes in a Warfarin-Treated Population With Atrial Fibrillation

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • American Medical Association (AMA),2016
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-329533
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-329533URI
  • https://doi.org/10.1001/jamacardio.2016.0199DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-124782URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:135886338URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • IMPORTANCE Vitamin K antagonist (eg, warfarin) use is nowadays challenged by the non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation (AF). NOAC studies were based on comparisons with warfarin arms with times in therapeutic range (TTRs) of 55.2% to 64.9%, making the results less credible in health care systems with higher TTRs. OBJECTIVES To evaluate the efficacy and safety of well-managed warfarin therapy in patients with nonvalvular AF, the risk of complications, especially intracranial bleeding, in patients with concomitant use of aspirin, and the impact of international normalized ratio (INR) control. DESIGN, SETTING, AND PARTICIPANTS A retrospective, multicenter cohort study based on Swedish registries, especially AuriculA, a quality register for AF and oral anticoagulation, was conducted. The register contains nationwide data, including that from specialized anticoagulation clinics and primary health care centers. A total of 40 449 patients starting warfarin therapy owing to nonvalvular AF during the study period were monitored until treatment cessation, death, or the end of the study. The study was conducted from January 1, 2006, to December 31, 2011, and data were analyzed between February 1 and November 15, 2015. Associating complications with risk factors and individual INR control, we evaluated the efficacy and safety of warfarin treatment in patients with concomitant aspirin therapy and those with no additional antiplatelet medications. EXPOSURES Use of warfarin with and without concomitant therapy with aspirin. MAIN OUTCOMES AND MEASURES Annual incidence of complications in association with individual TTR (iTTR), INR variability, and aspirin use and identification of factors indicating the probability of intracranial bleeding. RESULTS Of the 40 449 patients included in the study, 16 201 (40.0%) were women; mean (SD) age of the cohort was 72.5 (10.1) years, and the mean CHA(2)DS(2)-VASc (cardiac failure or dysfunction, hypertension, age >= 75 years [doubled], diabetes mellitus, stroke [doubled]-vascular disease, age 65-74 years, and sex category [female]) score was 3.3 at baseline. The annual incidence, reported as percentage (95% CI) of all-cause mortality was 2.19% (2.07-2.31) and, for intracranial bleeding, 0.44%(0.39-0.49). Patients receiving concomitant aspirin had annual rates of any major bleeding of 3.07%(2.70-3.44) and thromboembolism of 4.90% (4.43-5.37), and those with renal failure were at higher risk of intracranial bleeding (hazard ratio, 2.25; 95% CI, 1.32-3.82). Annual rates of any major bleeding and any thromboembolism in iTTR less than 70% were 3.81% (3.51-4.11) and 4.41% (4.09-4.73), respectively, and, in high INR variability, were 3.04%(2.85-3.24) and 3.48% (3.27-3.69), respectively. For patients with iTTR 70% or greater, the level of INR variability did not alter event rates. CONCLUSIONS AND RELEVANCE Well-managed warfarin therapy is associated with a low risk of complications and is still a valid alternative for prophylaxis of AF-associated stroke. Therapy should be closely monitored for patients with renal failure, concomitant aspirin use, and poor INR control.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Renlund, Henrik,1979-Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)henre358 (author)
  • Lip, Gregory Y. H.Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England.;Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark. (author)
  • Wester, PerKarolinska Institutet,Umeå universitet,Medicin(Swepub:umu)pewe0002 (author)
  • Svensson, Peter J.Lund Univ, Dept Coagulat Disorders, Malmo, Sweden. (author)
  • Själander, AndersUmeå universitet,Medicin,Sundsvall Research Unit, Umeå University(Swepub:umu)anssjr90 (author)
  • Umeå universitetMedicin (creator_code:org_t)

Related titles

  • In:JAMA cardiology: American Medical Association (AMA)1:2, s. 172-1802380-65832380-6591

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Björck, Fredrik
Renlund, Henrik, ...
Lip, Gregory Y. ...
Wester, Per
Svensson, Peter ...
Själander, Ander ...
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Cardiac and Card ...
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
Articles in the publication
JAMA cardiology
By the university
Uppsala University
Umeå University
Karolinska Institutet

Search outside SwePub

Wikipedia about the author:
Fredrik_Björck
Björck, Fredrik
en

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view